Tegafur + gimeracil + oteracil (Teysuno)
- Status:
- Red
- Decision Date:
- February 2022
Comments
RED: Use as monotherapy or in combination with oxaliplatin
or irinotecan, with or without bevacizumab, for the treatment of patients with
metastatic colorectal cancer for whom it is not possible to continue treatment with
another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity
that developed in the adjuvant or metastatic setting. NHSE commissioned. (Decision date - February 2022)
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again